Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
- PMID: 28631778
- DOI: 10.1701/2715.27717
Cost-effectiveness of first-line hormone-therapies in chemonaïve castration-resistant prostate cancer Integrating the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) with the costs of drugs
Comment on
-
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.Pharmacoeconomics. 2017 Feb;35(2):191-202. doi: 10.1007/s40273-016-0445-5. Pharmacoeconomics. 2017. PMID: 27566699 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
